The article discusses Samphire Neuroscience, a startup that has developed a wearable device called Nettle, which aims to help alleviate period pain in women. The device uses transcutaneous electrical nerve stimulation (TENS) technology to deliver pain relief and is being developed as a treatment for endometriosis and other menstrual disorders.
Here are some key points from the article:
- Regulatory certification: Samphire is working towards obtaining regulatory certification, which will be crucial in making Nettle available to the masses.
- Investors: The startup has received funding from several investors, including entities associated with the family of Russell Buckley.
- Market demand: While statistics suggest that 90% of women suffer some form of PMS and 91% experience pain during menstruation, it’s unclear what proportion will be willing to invest in a treatment device like Nettle.
- Potential for scaling sales: If the startup is successful, there could be potential for scaling sales via a B2B2C model, where health insurers reimburse the product or employers offer it as a support measure.
Overall, the article highlights the innovative approach Samphire is taking to tackle period pain and the potential for this technology to make a significant impact on women’s lives.
